From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis

Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance

(2018) Martin Wartenberg et al.   CLINICAL CANCER RESEARCH

Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.

(2018) Manuel M. Hidalgo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.

(2018) Andrea Wang-Gillam et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma

(2018) Ujjwal Mukund Mahajan et al.   GASTROENTEROLOGY

Hypermutation In Pancreatic Cancer

(2017) Jeremy L. Humphris et al.   GASTROENTEROLOGY

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

(2017) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

(2017) Vinod P. Balachandran et al.   NATURE

Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis

(2017) Yongxun Zhuan-Sun et al.   OncoTargets and Therapy

Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer

(2017) Jung-Eun Jang et al.   Cell Reports

Microsatellite Instability

(2017) Liisa Chang et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy

(2017) Floris Dammeijer et al.   Cancer Immunology Research

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.

(2017) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

(2017) Gustav J. Ullenhag et al.   PLoS One

CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids

(2016) D. Zboralski et al.   ANNALS OF ONCOLOGY

A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor (galunisertib) in combination with anti–PD-1 (nivolumab) in advanced refractory solid tumours

(2016) S.C. Guba et al.   ANNALS OF ONCOLOGY

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Microsatellite Instability as a Biomarker for PD-1 Blockade

(2016) J. C. Dudley et al.   CLINICAL CANCER RESEARCH

Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

(2016) Naoki Horikawa et al.   CLINICAL CANCER RESEARCH

The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery

(2016) Jun Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer.

(2016) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).

(2016) Irfan Firdaus et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

(2016) Emma Eriksson et al.   Journal of Translational Medicine

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

(2016) Katsuhiko Uesaka et al.   LANCET

Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment

(2016) Ann Hanna et al.   Molecular Cancer

Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25−T cells by activation of the TGF-β/β-catenin pathway

(2016) Xiaomin Kang et al.   MOLECULAR HUMAN REPRODUCTION

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-derived Suppressor Cells Recruit CD4+/Foxp3+ Regulatory T Cells in a Murine Cardiac Allograft

(2016) T. Nakamura et al.   TRANSPLANTATION PROCEEDINGS

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-β during Murine Colitis

(2016) Cho-Rong Lee et al.   Cell Reports

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

(2016) A. H. Long et al.   Cancer Immunology Research

Immunotherapy in pancreatic cancer treatment: a new frontier

(2016) Komal Thind et al.   Therapeutic Advances in Gastroenterology

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

(2016) Peter Bailey et al.   Scientific Reports

Emerging immune checkpoints for cancer therapy

(2015) Xiaodong Li et al.   ACTA ONCOLOGICA

Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma

(2015) Tomoya Kawase et al.   BMC GASTROENTEROLOGY

New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery

(2015) Archana Bhaw-Luximon et al.   CANCER LETTERS

Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer

(2015) Brian J. Lannutti et al.   CANCER RESEARCH

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

(2015) S. Takeuchi et al.   CANCER RESEARCH

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

The interaction of anticancer therapies with tumor-associated macrophages

(2015) Alberto Mantovani et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection

(2015) Zhong Fang et al.   JOURNAL OF IMMUNOLOGY

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism

(2015) Armando Rojas et al.   TUMOR BIOLOGY

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors

(2015) Diletta Di Mitri et al.   OncoImmunology

IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer

(2015) Serena Lunardi et al.   OncoImmunology

Lactic acid polarizes macrophages to a tumor-promoting state

(2015) Oscar R Colegio   OncoImmunology

Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models

(2015) Marine M Leblond et al.   OncoImmunology

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Galectin-1 Drives Pancreatic Carcinogenesis through Stroma Remodeling and Hedgehog Signaling Activation

(2014) N. Martinez-Bosch et al.   CANCER RESEARCH

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

(2014) J. Goldman et al.   CLINICAL CANCER RESEARCH

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

(2014) Ingunn M Stromnes et al.   GUT

Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

(2014) M. C. B. Tan et al.   JOURNAL OF IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer

(2014) Hideya Onishi   WORLD JOURNAL OF GASTROENTEROLOGY

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

(2014) E. R. Lutz et al.   Cancer Immunology Research

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

Hypoxia Triggers Hedgehog-Mediated Tumor-Stromal Interactions in Pancreatic Cancer

(2013) T. R. Spivak-Kroizman et al.   CANCER RESEARCH

Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma

(2013) Abasi Ene–Obong et al.   GASTROENTEROLOGY

Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma

(2013) Lei Zheng et al.   GASTROENTEROLOGY

Blocking SDF-1 /CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow-Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors

(2013) R. Hamdan et al.   MOLECULAR CANCER THERAPEUTICS

Tumor-associated macrophages: functional diversity, clinical significance, and open questions

(2013) Subhra K. Biswas et al.   Seminars in Immunopathology

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

(2013) Magali Terme et al.   OncoImmunology

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth

(2012) Wiebke Hansen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dangerous liaisons: Pancreatic stellate cells and pancreatic cancer cells

(2012) Minoti V Apte et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Epidemiology, risk factors, and the promotion of pancreatic cancer: Role of the stellate cell

(2012) Stephen Pandol et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

(2012) Jeffrey M. Hardacre et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth

(2012) E. Schlecker et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer

(2012) Andrew D. Gilliam et al.   PANCREAS

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer

(2011) Karl-Hermann Schlingensiepen et al.   CANCER SCIENCE

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

(2011) J. A. Kyte et al.   CLINICAL CANCER RESEARCH

Retinoic Acid–Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt–β-Catenin Signaling to Slow Tumor Progression

(2011) Fieke E.M. Froeling et al.   GASTROENTEROLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells

(2011) Vittore Cereda et al.   VACCINE

Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

(2010) Ghassan K. Abou-Alfa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?

(2010) Vegard Tjomsland et al.   BMC CANCER

19-nor-1α,25-Dihydroxyvitamin D2(Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo

(2010) Gary G. Schwartz et al.   CANCER BIOLOGY & THERAPY

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

(2010) Lei Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained

(2010) Jennifer S. Ko et al.   CANCER RESEARCH

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CCK1 and CCK2 Receptors Are Expressed on Pancreatic Stellate Cells and Induce Collagen Production

(2010) Marc J. Berna et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Circulating Myeloid Dendritic Cells as Prognostic Factors in Patients with Pancreatic Cancer Who Have Undergone Surgical Resection

(2010) Tomohisa Yamamoto et al.   JOURNAL OF SURGICAL RESEARCH

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

(2010) U. Bogdahn et al.   NEURO-ONCOLOGY

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

(2009) Motoki Miyazawa et al.   CANCER SCIENCE

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg

(2009) Hiroyuki Suzuki et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis

(2009) H. Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer

(2008) G. Feldmann et al.   MOLECULAR CANCER THERAPEUTICS

A paracrine requirement for hedgehog signalling in cancer

(2008) Robert L. Yauch et al.   NATURE

Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)

(2008) J. Weber   ONCOLOGIST

Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)

(2008) A. Ribas   ONCOLOGIST

Regulatory T Cells: Mechanisms of Differentiation and Function

(2007) Steven Z. Josefowicz et al.   Annual Review of Immunology